Anixa Biosciences Enhances Global Patent Protection
Anixa Biosciences, Inc., a leading player in the biotechnology sector devoted to developing innovative cancer treatment solutions, has taken a significant step in strengthening its international intellectual property portfolio. On November 19, 2026, the Canadian Intellectual Property Office officially issued Patent Number 3,005,025, which encompasses critical elements of Anixa's groundbreaking ovarian cancer vaccine technology.
The newly granted patent is particularly noteworthy as it provides Anixa with expanded protection for its vaccine that aims to leverage the body's immune system to either prevent or treat ovarian cancer. This enhancement is especially vital for populations at heightened risk, such as individuals with BRCA mutations or those with a family history of the disease.
Innovative Approach to Cancer Treatment
The patented technology, which is exclusively licensed from the prestigious Cleveland Clinic, is titled "Ovarian Cancer Vaccines" and was co-invented by Dr. Justin Johnson, the late Dr. Vincent Tuohy, and Dr. Suparna Mazumder from Cleveland Clinic. The patent details methods of immunization targeting the anti-Müllerian hormone receptor II (AMHR2-ED), a protein that is produced in normal ovaries before menopause and is also found to be abnormally expressed in certain ovarian cancer forms.
Anixa's approach employs what is referred to as the "retired" protein strategy, developed at Cleveland Clinic and exclusively licensed to Anixa. This strategy is designed to instruct the immune system to recognize and eliminate cancerous cells while minimizing the impact on healthy tissue. By capitalizing on the differences in protein expression between normal and cancerous cells, Anixa's vaccine could provide a novel pathway for both cancer prevention and treatment.
Broader Vaccine Initiatives
Notably, this patented ovarian cancer vaccine exists within a wider portfolio of vaccines being developed by Anixa, which also includes an investigational breast cancer vaccine in collaboration with Cleveland Clinic. Recently, the breast cancer vaccine concluded a Phase 1 clinical trial funded by a grant from the U.S. Department of Defense, achieving all primary endpoints, which underscores the potential of Anixa’s innovative technologies.
Anixa believes that by targeting proteins associated with various cancers, there is a unique opportunity to create preventive vaccines for multiple types of malignancies. The recent Canadian patent issuance complements Anixa's existing patent protection in the United States, where a U.S. Patent Number 12,357,593 was granted in July 2025, covering essential aspects of their ovarian cancer vaccine technology, including broad claims related to eliciting immune responses targeting AMHR2-ED.
CEO’s Perspective on Future Directions
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed enthusiasm regarding the new patent, stating, “This Canadian patent further strengthens the international patent protection around our ovarian cancer vaccine program and reinforces our intellectual property position in our AMHR2-ED-targeted immunoprevention approach. We believe vaccines designed to prevent cancer represent an important frontier in oncology.”
The long-term vision for this ovarian cancer vaccine focuses on preempting the disease before it manifests, merging scientific innovation with patient care for proactive cancer treatment solutions. By enhancing its patent portfolio, Anixa aims to accelerate the advancement of this technology and expand its suite of cancer prevention vaccines.
About Anixa Biosciences
Anixa Biosciences, based in San Jose, California, is a clinical-stage biotechnology firm committed to transforming cancer treatment and prevention methodologies. The company's diverse therapeutic portfolio includes not only the ovarian cancer immunotherapy in collaboration with Moffitt Cancer Center but also innovative vaccine technologies developed with the Cleveland Clinic aimed at tackling numerous challenging cancers such as lung, colon, and prostate malignancies. Anixa's collaborative approach with world-renowned research institutions allows for continuous evaluation and development of emerging technologies in complementary fields, ensuring the company stays at the forefront of cancer research.
To learn more about Anixa and its innovative cancer treatments, visit
www.anixa.com or follow them on social media platforms like LinkedIn, X, Facebook, and YouTube.